China's Pharmaceutical Industry Has Been Growing at 20% on the Average in Production...

Wed Jan 9, 2008 7:25am EST

* Reuters is not responsible for the content in this press release.

China's Pharmaceutical Industry Has Been Growing at 20% on the Average in Production Value over the Past Decade

DUBLIN, Ireland--(Business Wire)--Research and Markets
(http://www.researchandmarkets.com/reports/c79015) has announced the
addition of "China Biopharmaceutical Industry Report, 2007-2008" to
their offering

   The pharmaceutical industry is a sunrise industry, especially
biopharmaceuticals, which has just started its large-scale
industrialization process. Many large biotech and pharmaceutical
companies are strengthening their presence worldwide. Compared with
traditional pharmaceutical industry, biopharmaceutical industry sees a
higher market concentration, and this is more helpful for strong
enterprises to grow stronger and for building a number of leading
enterprises in the segment areas. Currently, traditional chemical
pharmaceutical makers have also started turning their eyes towards the
biopharmaceutical field, and keep themselves busy in establishing much
more strategic alliances.

   China's pharmaceutical industry has been growing at 20% on the
average in production value over the past decade, nearly doubling
every four years. In Jan-Jul 2007, the accumulated production value of
the entire industry reached RMB 342.449 billion, up 23.47% compared to
the same period of last year, of which, the production value of
bio-pharmaceuticals was RMB 30.229 billion, up 24.37% from a year
earlier.

   China's biopharmaceutical industry could not only produce
internationally important biologic drugs, but develop independently
new biological drugs. Furthermore, China has achieved great
breakthroughs in gene engineering, biopharmaceuticals and clone
technology. Despite the rapid growth, there are still serious problems
in China's biopharmaceutical industry:

   -China is weak in the investment, R&D capability and technology
innovation;

   -There are serious repeated construction problems in drug
development and production;

   -Overall, enterprises are small-sized, and with low modernization
level and outmoded equipments;

   -Marketing strategies are unreasonable, mainly in brand
development;

   -Management is outdated and talents capable of both technology and
operation fall short;

   There is not enough exchange and cooperation among enterprises.

   The biopharmaceutical industry includes four segment markets: gene
engineering, bacterin, blood products and diagnostic reagent. After
more than a decade of development, these four segment markets find
many aggressive private or state-owned biopharmaceutical enterprises
through which China is to fulfill its supports to the whole industry.
As far as capital market is concerned, as the concept investment
bubble fades away, Chinese pharmaceutical enterprises are expected to
be gradually accepted by the market with its high growth potentials.

   Policies have a great influence on China's biopharmaceutical
industry, so how much effort China will make to support the industry
plays a significant role in its development. In fact, China always
keeps a close eye on the biopharmaceutical industry and has frequently
issued related policies in the last two years, which is very positive
for stimulating the development ofthe biopharmaceutical industry and
for regulating industry rules, and also brings energy and
opportunities into the biopharmaceutical industry.

   Based on the study on China's pharmaceutical industry's status
quo, competitive pattern, investment and developing trend, this report
puts its emphasis on output and the sales situation of main drugs, the
impact China's pharmaceutical industry will face as well as strategies
enterprises should make.

   Contents:

   1 Operation Status of China Pharmaceutical Industry in 2007

   1.1 Overview

   1.2 Problems in China pharmaceutical market

   1.2.1 Competition in production is rampant

   1.2.2 Capability in innovation is poor

   1.2.3 Drug quality appears thread-and-thrum

   1.2.4 Financing channel is undiversified and investment is in
short supply

   1.2.5 Drug circulation market is unorderly

   1.3 Policies adjustment in China's pharmaceutical industry in 2007

   2 Overview of Biopharmaceutical Industry

   3 Environments in China Biopharmaceutical Industry

   4 Status Quo of China Biopharmaceutical Industry

   5 Industrial Systems in China Biopharmaceutical Industry

   6 Main biopharmaceutical products

   7 Listed Companies

   8 Foreign Companies in China

   Selected Charts

   For more information visit
http://www.researchandmarkets.com/reports/c79015

Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008